Skip to Main Content

Paper Details

Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis.
Mol Ther
9
2022
Author NameAffiliation
Elizabeth M Jaffeethe Johns Hopkins University School of Medicine, USA Sidney Kimmel Cancer Center, the Johns Hopkins University
Elana J FertigJohns Hopkins University School of Medicine, the Johns Hopkins University School of Medicine, USA Sidney Kimmel Cancer Center, the Johns Hopkins University, Johns Hopkins University, USA Convergence Institute
Denis WirtzJohns Hopkins University, USA Institute for Nano Biotechnology (INBT), the Johns Hopkins University, the Johns Hopkins University School of Medicine, USA Sidney Kimmel Cancer Center
  • 1 - 3

Datasets